The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) who were previously treated with ruxolitinib. Participants will represent the overall patient population with PMF, post-PV MF or post-ET MF who lost adequate response to and/or are intolerant to ruxolitinib. Inadequate response definitions will follow Ministry of Food and Drug Safety-approved label and reimbursement criteria of the Health Insurance Review \& Assessment Service.
Study Type
OBSERVATIONAL
Enrollment
137
According to the approved label
Bristol-Myers Squibb YH
Seoul, South Korea
RECRUITINGLocal Institution - 0001
Seoul, South Korea
TERMINATEDNovotech Laboratory Korea Co., Ltd.
Seoul, South Korea
RECRUITINGNumber of participants with adverse events
The type, frequency, seriousness and severity of adverse events (AEs), and relationship of AEs to Inrebic® (fedratinib)
Time frame: Up to 6 months
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.